Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Poseida Therapeutics (PSTX)
NASDAQ:PSTX
RESEARCH TOOLSreports
Holding PSTX?
Track your performance easily
PSTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.87 - $4.27
Previous Close$2.73
Volume286.32K
Average Volume (3M)490.37K
Market Cap
$266.08M
Enterprise Value$117.95M
Total Cash (Recent Filing)$230.85M
Total Debt (Recent Filing)$82.73M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Mar 06, 2025EPS Estimate
-$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding97,465,024
10 Day Avg. Volume707,115
30 Day Avg. Volume490,369
Standard Deviation0.20
R-Squared0.02
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)3.06
Price to Sales (P/S)1.79
Price to Cash Flow (P/CF)-7.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.78
Enterprise Value/Gross Profit1.82
Enterprise Value/Ebitda-2.64
Forecast
1Y Price Target
$14.00Price Target Upside389.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Poseida Therapeutics News
Ownership Overview
2.78% Insiders
16.92% Mutual Funds
14.63% Other Institutional Investors
58.57% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PSTX FAQ
What was Poseida Therapeutics’s price range in the past 12 months?
Poseida Therapeutics lowest stock price was $1.87 and its highest was $4.27 in the past 12 months.
What is Poseida Therapeutics’s market cap?
Currently, no data Available
When is Poseida Therapeutics’s upcoming earnings report date?
Poseida Therapeutics’s upcoming earnings report date is Mar 06, 2025 which is in 100 days.
How were Poseida Therapeutics’s earnings last quarter?
Poseida Therapeutics released its earnings results on Nov 07, 2024. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of -$0.418 by $0.628.
Is Poseida Therapeutics overvalued?
According to Wall Street analysts Poseida Therapeutics’s price is currently Undervalued.
Does Poseida Therapeutics pay dividends?
Poseida Therapeutics does not currently pay dividends.
What is Poseida Therapeutics’s EPS estimate?
Poseida Therapeutics’s EPS estimate is -$0.33.
How many shares outstanding does Poseida Therapeutics have?
Poseida Therapeutics has 97,465,030 shares outstanding.
What happened to Poseida Therapeutics’s price movement after its last earnings report?
Poseida Therapeutics reported an EPS of $0.21 in its last earnings report, beating expectations of -$0.418. Following the earnings report the stock price went up 5.119%.
Which hedge fund is a major shareholder of Poseida Therapeutics?
Among the largest hedge funds holding Poseida Therapeutics’s share is Woodline Partners LP. It holds Poseida Therapeutics’s shares valued at 1M.
---
Poseida Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.00 (389.51% Upside)
$14.00 (389.51% Upside)
Blogger Sentiment
Bullish
PSTX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 575.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.59%
12-Months-Change
Fundamentals
Return on Equity
-57.63%
Trailing 12-Months
Asset Growth
-2.87%
Trailing 12-Months
Company Description
Poseida Therapeutics
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumors.
---
PSTX Stock 12 Month Forecast
Average Price Target
$14.00
▲(389.51% Upside)
Technical Analysis
Best Analysts Covering PSTX
1 Year
1 Year Success Rate
9/20 ratings generated profit
1 Year Average Return
+3.56%
reiterated a buy rating 2 months ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 45.00% of your transactions generating a profit, with an average return of +3.56% per trade.
---